# Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

> **NCT07371234** · PHASE2 · RECRUITING · sponsor: **Xiwei XU** · enrollment: 22 (estimated)

## Conditions studied

- Locally Advanced Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Neoadjuvant and Adjuvant Immunotherapy
- **RADIATION:** Low-dose radiotherapy
- **PROCEDURE:** Surgery
- **RADIATION:** Adjuvant Radiotherapy
- **DRUG:** Adjuvant Cisplatin

## Key facts

- **NCT ID:** NCT07371234
- **Lead sponsor:** Xiwei XU
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-15
- **Primary completion:** 2027-01-15
- **Final completion:** 2028-12-30
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07371234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07371234, "Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07371234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*